Sign in to view content

Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy

Michael J Allingham, MD, PhD

Video
Published 2022

Related

Preliminary Results from a First-in-human Phase I/II Gene Therapy Study (FOCUS) of Subretinally Delivered GT005, an Investigational AAV2 Vector, in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration
Jared S. Nielsen, MD, MBA
Updates from the Field
2022
Diabetic Retinopathy Progression in Anti-VEGF Versus Fluocinolone Acetonide Implant Treated Eyes Who Are Lost to Follow-up
Caesar K. Luo, MD, FASRS
Annual Meeting Talks
2020
Outcomes of DRCR Network Treatment Regimen Starting with Observation for Eyes With Center-involved Diabetic Macular Edema and Good Visual Acuity
Omar S. Punjabi, MD
Updates from the Field
2019

Category: Diabetic Retinopathy

See more